Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Mylan receives FDA approval for generic Sporanox ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Itraconazole Capsules, 100 mg.

27 Jul 2012

Jersey Shore continues to provide outstanding cardiac surgery services

The 2012 Cardiac Surgery in New Jersey report, recently released by the New Jersey Department of Health & Senior Services (NJDHSS), shows Jersey Shore University Medical Center continues to provide outstanding cardiac surgery services, building on its exceptional track record in coronary artery bypass graft (CABG) surgery mortality rates.

24 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

Prostate cancer treatment regrets linked to comorbidity

Men with cardiovascular disease are significantly more likely to regret their prostate cancer treatment choice than men without this comorbidity and have an increased risk for adverse effects, US researchers warn.

16 Jul 2012

Early surgery best for infective endocarditis

Compared with conventional treatment, early surgery for patients with infective endocarditis and large vegetations significantly reduces the risk for death or embolic events by reducing the risk for systemic embolism, show results from a randomized trial.

12 Jul 2012

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.

12 Jul 2012

Humana acquires national chronic-care provider, SeniorBridge

Humana Inc. announced today it has completed its acquisition of SeniorBridge, a national chronic-care provider best known for providing in-home care management and caregiving services for seniors.

9 Jul 2012

Prostate cancer patients with CVD are 52% more likely to regret their treatment choices

Prostate cancer patients with cardiovascular disease were 52 per cent more likely to regret their treatment choices than men without problems with their heart or veins, according to a study published in the July issue of the urology journal BJUI International.

3 Jul 2012

Savient's KRYSTEXXA improves HRQOL and physical function in patients with RCG

Savient Pharmaceuticals, Inc. announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.

3 Jul 2012

Arena receives FDA approval for Belviq to treat obesity

The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.

28 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

AMAG Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).

23 Jun 2012

C-section rates in US stabilize after eight years of steady increase

A new report on trends in women's health in the United States reveals the national C-section rate has held steady at 33 percent since 2009, leveling off after eight years of steady increase that was in part driven by scheduled, elective surgeries and a trend for increasing the repeat C-section.

19 Jun 2012

Better care for dual-eligible Medicare-Medicaid patients could reduce hospitalization rates

Providing better care for dual-eligible Medicare-Medicaid patients could significantly reduce hospitalization rates for this population, saving taxpayers between $625 million and $1.9 billion per year, according to a new study by researchers at RTI International and Florida Atlantic University.

15 Jun 2012

Digoxin can protect against high blood pressure and heart failure

An ancient heart drug that's inspired the work of herbalists and poets for centuries may treat a condition that plagues millions of overstressed and overweight Americans today.

15 Jun 2012

Mixed picture for pulse pressure effect on surgical outcomes

Two studies published in Anesthesia and Analgesia have muddied the water regarding the effect of preoperative pulse pressure on perioperative outcomes.

13 Jun 2012

Study reviews data on influence of contralateral carotid occlusion on CEA and CAS

A new study, presented at the 66th Vascular Annual Meeting presented by the Society for Vascular Surgery (SVS) reviewed data on the influence of contralateral carotid occlusion (CCO) on carotid endarterectomy (CEA) and carotid artery stenting (CAS) for which there is a paucity of conflicting data.

11 Jun 2012